Danaher (NYSE: DHR) — Company Overview, News & Financial Data
Danaher is a global enterprise focused on life sciences, diagnostics, and healthcare, driving technological innovation.
Danaher
Danaher is a global science and technology innovator operating in biotechnology, diagnostics, and life sciences. The company designs, manufactures, and markets advanced instruments, equipment, software, and consumables used in medical research, clinical diagnostics, and biopharmaceutical production. Its biotechnology operations support bioprocessing, biomanufacturing, and cell and gene therapy development. The diagnostics segment provides automated diagnostic systems, pathology tools, and point-of-care testing equipment for hospitals and laboratories. Its life sciences segment offers filtration, analytical instrumentation, and microscopy solutions. Headquartered in Washington, D.C., Danaher operates research, manufacturing, and commercial facilities across North America, Europe, and Asia-Pacific.
Snapshot
Operations
Products and/or services of Danaher
- Bioprocessing Technologies: Provision of advanced bioprocessing equipment, filtration membranes, chromatography media, single-use bioreactors, and cell culture media essential for accelerating biopharmaceutical development, purification, and large-scale commercial drug manufacturing across global biopharmaceutical facilities.
- Cell and Gene Therapy Solutions: Specialized technologies, reagents, viral vector manufacturing tools, and cell processing systems supporting researchers and pharmaceutical manufacturers in developing, scaling, and manufacturing targeted cell and gene therapies safely.
- Clinical Diagnostic Instruments: Automated clinical chemistry analyzers, immunoassay test platforms, acute care testing systems, and reagents supplied to hospitals and reference laboratories to enable rapid, high-throughput clinical testing and patient diagnoses.
- Anatomic Pathology and Molecular Diagnostics: Advanced tissue diagnostic instruments, automated slide stainers, digital pathology scanners, and molecular testing platforms designed for precise disease detection, oncology analysis, and anatomic pathology laboratory workflows worldwide.
- Life Science Analytical Instrumentation: High-resolution mass spectrometry systems, flow cytometers, automated liquid handling robotics, and capillary electrophoresis platforms deployed across academic research institutions, biotechnology firms, and pharmaceutical research and development laboratories.
- Laboratory Filtration and Separation Systems: High-purity lab filtration membranes, purification cartridges, fluid management components, and sample preparation equipment utilized in biopharmaceutical discovery, environmental monitoring, microelectronics manufacturing, and industrial testing operations.
Danaher executive team
- Steven M. RalesCo-Founder & Chairman
- Julie Sawyer MontgomeryPresident, CEO & Director
- Mitchell P. RalesCo-Founder & Director
- Jose-Carlos Gutierrez-RamosSenior VP & Chief Science Officer
- Matthew R. McGrewExecutive Vice President
- Rainer M. BlairSenior Advisor
- Christopher Paul RileyExecutive VP of Biotechnology Group & CEO of Cytiva
- Matthew E. GuginoExecutive VP & CFO
- Christopher M. BoudaVP & Chief Accounting Officer
- Rachel Marie Vatnsdal OlsonVice President of Investor Relations
Latest news about Danaher
Danaher Q3 revenue ralies 8.5% to $6.55 billion
United StatesDanaher partners with NVIDIA on AI labs
United StatesDanaher reports $870M Q2 2026 net earnings and raises guidance
United StatesDanaher completes acquisition of Masimo, expanding diagnostics portfolio
United StatesDanaher delivers robust Q1 2026 results and announces strategic move
United StatesDanaher to buy Masimo in $9.9 billion cash deal
United States
Dividend history
Dividends per share paid by Danaher , by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2026(to date) | — | — | — | $1.2000 |
| FY2025 | — | — | — | $1.2800 |
| FY2024 | — | — | — | $1.0800 |
| FY2023 | — | — | — | $0.9887 |
| FY2022 | — | — | — | $0.8865 |
Key financials
Reported results for Danaher , in USD.
- Market cap
- 164.5B
- Revenue (TTM)
- 25.6B
- P/E ratio
- 38.8
- EPS (diluted, TTM)
- 6.0
- Dividend yield
- 0.7%
- Profit margin
- 16.9%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 24.6B | 5.1B | 3.6B | |
| 23.9B | 5.2B | 3.9B | |
| 23.9B | 5.2B | 4.7B | |
| 26.6B | 7.5B | 7.2B |